#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Familial amyotrophic lateral sclerosis Hodgkin's disease recurrent Follicle centre lymphoma follicular grade I, II – III Pseudomyxoma peritonei Antithrombin III deficiency Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Nodal marginal zone B-cell lymphoma Loss of consciousness Barth syndrome Glioma Head and neck cancer Osteogenesis imperfecta Biotinidase deficiency PIK3CA-activated mutation Adult T-cell lymphoma/leukaemia refractory More trials…

    Learn about Rare Diseases

    Pulmonary sarcoidosis – Life with Disease Wolfram syndrome – Treatment Nodal marginal zone B-cell lymphoma Glomerulonephritis membranous – Treatment Carcinoid syndrome – Treatment Metachromatic leukodystrophy – Treatment Angiosarcoma recurrent Ocular melanoma Medulloblastoma – Basic Information Mantle cell lymphoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pervi-Fus Valine Ranitidine Afimetoran Besilate Dihydrate Phentermine Clazakizumab ATUMELNANT Fluconazole Dorzolamide Hydrochloride Carbamazepine (Ph. Eur.) Balcinrenone Anselamimab Dornase Alfa Dalteparin Sodium Levocarnitine Oric-114 Mva-Hbvac Granisetron Mezigdomide T89 More therapies…

    Learn about Your Condition

    Malignant oligodendroglioma Mucopolysaccharidosis II Acute hepatic failure Thromboembolectomy Cardiomyopathy Breast cancer male Breast angiosarcoma Atopic keratoconjunctivitis Von Willebrand's disease Rectal cancer Muscle hypertrophy Wiskott-Aldrich syndrome Varicella Osteomyelitis acute Asplenia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer

  • Study of JNJ-90301900 with Chemoradiation and Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • HAFNIUM OXIDE
    France The Netherlands Spain

  • Study on Tedopi and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer After Initial Treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • D-Ala-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-D-Ala
    • Mps-102
    • Mps-103
    France Italy Spain

  • Study on Fexofenadine Hydrochloride and Immunotherapy for Patients with Advanced Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Fexofenadine Hydrochloride
    Austria

  • Study on EGFR-Mutated Lung Cancer: Evaluating Dacomitinib, Afatinib, and Osimertinib for Patients Not Suitable for Curative Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Dacomitinib
    • Afatinib
    • Osimertinib
    Sweden

  • Study on PET Imaging with Fianlimab and Cemiplimab for Patients with Advanced Solid Tumors, with or without Platinum-Based Chemotherapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Microsatellite instability cancer
    • Cervix carcinoma
    Investigated Drugs:
    • Fianlimab
    • Cemiplimab
    The Netherlands

  • Study on the Safety and Effectiveness of Osimertinib and Datopotamab Deruxtecan for Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Osimertinib
    • Datopotamab Deruxtecan
    France Germany Italy Poland Spain
Previous Page
1 … 7 8 9 10 11 … 54
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!